Alendronate sodium is a bisphosphonate that acts as a specific inhibitor of osteoclastmediated bone resorption. Bisphosphonates are synthetic analogs of pyrophosphate that bind to the hydroxyapatite found in bone. Alendronate sodium is chemically described as (4-amino-1-hydroxybutylidene) bisphosphonic acid monosodium salt trihydrate. The empirical formula of alendronate sodium is C4H12NNaO7P2•3H2O, its formula weight is 325.12, and the CAS NO is 121268-17-5. Alendronate sodium is a white, crystalline, nonhygroscopic powder. It is soluble in water, very slightly soluble in alcohol, and practically insoluble in chloroform. Alendronate sodium tablets for oral administration contain 91.37 mg of alendronate monosodium salt trihydrate, which is the molar equivalent of 70 mg of free acid, and the following inactive ingredients: microcrystalline cellulose, anhydrous lactose, croscarmellose sodium, and magnesium stearate. Alendronate sodium is mainly used to cure following disease: Prophylaxis and treatment of female osteoporosis Treatment of male osteoporosis Prevention and treatment of corticosteroid-associated osteoporosis together with supplements of calcium and vitamin D Paget's disease Experimental treatment for Osteogenesis imperfecta Alendronate sodium inhibits osteoclast-mediated bone-resorption. Like all bisphosphonates, it is chemically related to inorganic pyrophosphate, the endogenous regulator of bone turnover. But while pyrophosphate inhibits both osteoclastic bone resorption and the mineralization of the bone newly formed by osteoblasts, it specifically inhibits bone resorption without any effect on mineralization at pharmacologically achievable doses. Its inhibition of bone-resorption is dose-dependent and approximately 1,000 times stronger than the equimolar effect of the first bisphosphonate drug, etidronate. Under therapy, normal bone tissue develops, and Alendronate sodium is deposited in the bone-matrix in pharmacologically inactive form. For optimal action, enough calcium and vitamin D are needed in the body in order to promote normal bone development. Hypocalcemia should, therefore, be corrected before starting therapy. Etidronate has the same disadvantage as pyrophosphate in inhibiting mineralization, but all of the potent N-containing bisphosphonates including Alendronate sodium and also risedronate, ibandronate, and zoledronate, do not. Before taking this medicine, tell your doctor or pharmacist if you are allergic to it; or to other bisphosphonates; or if you have any other allergies. Alendronate sodium may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details. Before using Alendronate sodium, tell your doctor or pharmacist your medical history, especially of: disorders of the esophagus (such as esophageal stricture or achalasia), trouble swallowing, trouble standing or sitting upright for at least 30 minutes, low calcium levels, stomach/intestinal disorders (such as ulcers). Infrequently, people taking bisphosphonates have had serious jawbone problems (osteonecrosis). Poor dental hygiene, poorly fitting dentures, or having certain dental work. Want to learn more information about Alendronate sodium, you can access the guidechem.com. Guidechem.com is just a place for you to look for some chemicals.
Related Articles -
Alendronate sodium, 121268-17-5, guidechem,
|